Assume you have a drug nebivolol. When nebivolol is used as beta1 selective drug, beta2 is mostly for side effects, but this is not clear from PubChem. I do not know any cases where nebivolol is used as beta1 and beta2 selective in the treatment.
Its first two pathways of interaction from PubChem.
Assume this pathway to be selective for some indication
and this nonselective (where side-effects stems mostly with large doses)
There no such differences in this section. No explanations when side-effects come in each case of treatment plan (dose).
How can you understand side-effects of this adrenoblocker from selective beta1 pathway in PubChem? Like in which cases beta2 selection becomes possible when beta1 is selective. When beta2 is nonselective when beta1 is kept selective?
In other words, how can you read pharmacodynamics of this adrenoblocker in PubChem? I.e. what the drug does to the body at any given dose. I think there is little pieces of informations about it.
Implicitly, the side-effect can be read from Mechanism of Action:
where it refers at high doses to bronchospasm. However, I would refer explicit discussion about side-effects and what we are trying to find and what are suspected as side-effects.